10 December 2008, Mumbai:  Kotak Securities, the stock broking arm of the Kotak Mahindra group today announced the launch of Smart Order, a new service from, Kotak Securities that will help clients buy and sell stocks at the best possible rates from either of the stock exchanges – BSE or NSE.

Prasanth Prabhakaran, Senior Vice President & All India Head for Broking, commenting at the launch of this new service, said, “Smart Order is a novel concept introduced by Kotak Securities in the online broking space. Till date the online customer had to manually inspect and select the exchange to get a better price for his transaction. But with this system, Kotak Securities will help them get the best quoted price amongst NSE & BSE. There are price differences available in the market. Smart Order exploits these differences to benefit the customer. The investors can check the key features of this service on our website www.kotaksecurities.com.”

The Smart Order endeavors to offer the customer the best available price between NSE & BSE. Once he selects Smart Order to buy or sell, it executes the order at the best combination of price and quantity by doing a dynamic search. It is in fact better than having a dealer who decides the choice of stock exchange that will give you a better price and then executes the deal and all this instantly.

Smart Order is available without any extra charge and will be provided to all online clients of  Kotak Securities.

Hyderabad, India, December 10, 2008: Dr. Reddy’s Laboratories (NYSE:RDY) today announced that Betapharm AG, its wholly owned subsidiary, has received complete information on the preliminary result of the tender by the Allgemeine Ortskrankenkassen (AOK) for discount agreements for 47 of the 48 products pertaining to Betapharm, pursuant to § 130a SGB V.  betapharm has been tentatively offered 8 products in different regions of Germany covering the AOK-insured persons.
The tender procedure is yet to be concluded and is expected to face potential legal objections by several companies. On signing the final contracts with AOK, betapharm will be the sole supplier for AOK-insured persons for these 8 products in the awarded regions.
VS Vasudevan, President, European Operations, Dr. Reddy’s, said, “The preliminary results of the AOK tender establish betapharm’s competitiveness in the tender segment of the market in Germany. For the 8 products offered, we expect a significant increase in volume though at relatively lesser margins and for the balance portfolio, we expect the competitive intensity to continue.”
“Over the last few years, betapharm has aligned its sales force to strengthen relationships with doctors, pharmacies as well as channel partners. We leveraged Dr. Reddy’s vertical integration and global supply chain capabilities to strengthen the supply chain for this market. beta institute (the groups’ non-profit organization) complements these capabilities with the long-term goodwill it has built with the medical community through several years of Corporate Social Responsibility programmes. We believe that betapharm is well positioned to leverage all these strengths to continue to build a competitive business in all segments of the generics market in Germany”, said Satish Reddy, MD and COO, Dr. Reddy’s.